|Awarded On||February 21, 2018|
|Title||Hippo signaling in non-alcoholic fatty liver disease (NAFLD) and it progression to hepatocellular carcinoma|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Randy Johnson|
|Cancer Sites||Gallbladder, Liver and Intrahepatic Bile Duct|
Liver cancer is the fifth most common malignancy and is the third cause of cancer related deaths world wide with poor clinical prognosis, especially when diagnosed at advanced stages. Liver cancer incidence is increasing, in part to major risk factors including non-alcoholic fatty liver disease and non-alcoholic steatohepatitis that is prevalent in Western populations, including the United States and especially in Texas. We have partnered with Ionis Pharmaceuticals to develop their unique technology to target molecules and pathways previously thought to be “undruggable” leading to effective targeted therapy in preclinical models for liver cancer. Ionis has demonstrated experience in achievin...